Psoriasis – Landscape & Forecast – Disease Landscape & Forecast
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is increasingly being challenged by novel, highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of risankizumab (AbbVie’s Skyrizi)—the latest IL-23 inhibitor to be approved for psoriasis—has been phenomenal, raising concerns among developers of other approved biologics regarding the future uptake of their agents. The launches of deucravacitinib, an oral tyrosine kinase (TYK)2 inhibitor, and the nonsteroidal topical agents roflumilast and tapinarof have further increased the number of psoriasis treatments. Also, the anticipated approval of bimekizumab in the United States, following its approvals in Europe and Japan, will make the market even more competitive.
Questions answered:
- How do interviewed KOLs view the efficacy and safety of the IL-17 A inhibitors (Cosentyx, Taltz, Siliq / Lumicef) and the IL-17 A/F dual inhibitor bimekizumab, and where are/will these agents be positioned in the psoriasis treatment algorithm?
- What will be the impact of latest-to-market IL-23 inhibitors (Ilumya and Skyrizi) on TNF-alpha inhibitors, anti-IL-17s, and the first-in-class IL-23 inhibitor, Tremfya? How will these newer agents perform in the competitive psoriasis market?
- How will the oral TYK2 inhibitor deucravacitinib affect apremilast’s (Amgen’s Otezla) patient share, and how will the two agents compare on efficacy and safety attributes?
- What will be the future of the novel topical therapies roflumilast, a PDE-4 inhibitor, and tapinarof, a TAMA?
Content highlights:
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 36 country-specific interviews with thought leaders. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.
Emerging therapies: Phase III/PR: 2 drugs; Phase II: 10 drugs; coverage of select preclinical and Phase I products.
Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2031, segmented by brands/generics and epidemiological subpopulations.
Product description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement:
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Psoriasis - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- Q4 2022
- November 2022
- Q3 2022
- August 2022
- July 2022
- Q2 2022
- June 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- November 2021
- Q4 2022
- Market outlook
- Key findings
- Market share of psoriasis drug classes in 2021
- Market share of psoriasis drug classes in 2031
- Psoriasis SWOT analysis
- Market drivers and constraints
- What factors are constraining the market for psoriasis?
- Major-market sales of select drug classes in psoriasis: 2021-2031
- Annual sales of biologics and key oral agents in psoriasis: 2021-2031
- Drug-class-specific trends
- Patient share of TNF-alpha inhibitors in moderate to severe psoriasis by country: 2021-2031
- Brand and biosimilar patient share for TNF-alpha inhibitors in psoriasis: 2021-2031
- Major-market sales of TNF-alpha inhibitors and IL-12/23 inhibitors in moderate to severe psoriasis: 2021-2031
- Major-market patient share of TNF-alpha Inhibitors, IL-12/23 inhibitors, and IL-17 inhibitors in moderate to severe psoriasis: 2021-2031
- Major-market patient share of TNF-alpha inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, and IL-23 inhibitors in moderate to severe psoriasis: 2021-2031
- TYK2 inhibitors
- Major-market sales of biologics and novel oral therapies in moderate to severe psoriasis: 2021-2031
- Major-market patient share of traditional oral drug classes, PDE-4 inhibitors, A3 adenosine receptor agonists, and TYK2 inhibitors in moderate to severe psoriasis: 2021-2031
- Major-market sales of traditional oral drug classes, PDE4 inhibitors, A3 adenosine receptor agonists, and TYK2 inhibitors in moderate to severe psoriasis: 2021-2031
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and pathophysiology
- Etiology
- Risk factors
- Pathophysiology
- Clinical features
- Typical locations of psoriasis lesions
- Classification of psoriasis vulgaris by phenotype
- Clinical forms of psoriasis
- Key pathways and drug targets
- Pathogenesis of psoriasis and therapeutic targets
- Pathogenesis and drug targets
- Etiology
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods and sources used
- Number of diagnosed symptomatic prevalent cases of psoriasis in the major pharmaceutical markets:u00a02021-2031
- Disease definition
- Methods and sources used
- Sources used for drug-treated cases of psoriasis
- Number of diagnosed and drug-treated prevalent cases of mild psoriasis in the major pharmaceutical markets: 2021-2031 (thousands)
- Number of diagnosed and drug-treated prevalent cases of moderate to severe psoriasis in the major pharmaceutical markets: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for psoriasis
- Key physician insights on clinical endpoints
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for psoriasis
- Current therapies used for mild psoriasis
- Current therapies used for moderate to severe psoriasis
- Market events impacting the use of key current therapies in psoriasis
- Advantages and disadvantages of etanercept
- Expert insight: etanercept
- Advantages and disadvantages of infliximab
- Expert insight: infliximab
- Advantages and disadvantages of adalimumab
- Expert insight: adalimumab
- Advantages and disadvantages of certolizumab pegol
- Expert insight: certolizumab pegol
- Advantages and disadvantages of ustekinumab
- Expert insight: ustekinumab
- Advantages and disadvantages of secukinumab
- Expert insight: secukinumab
- Ongoing clinical development of Cosentyx
- Key ongoing clinical trials of Cosentyx in the treatment of new-onset moderate to severe psoriasis
- Advantages and disadvantages of ixekizumab
- Expert insight: ixekizumab
- Advantages and disadvantages of brodalumab
- Expert insight: brodalumab
- Advantages and disadvantages of bimekizumab
- Expert insight: bimekizumab
- Key ongoing clinical trials of bimekizumab in the treatment of psoriasis
- Advantages and disadvantages of guselkumab
- Expert insight: guselkumab
- Advantages and disadvantages of tildrakizumab
- Expert insight: tildrakizumab
- Advantages and disadvantages of risankizumab
- Expert insight: risankizumab
- Advantages and disadvantages of apremilast
- Expert insight: apremilast
- Advantages and disadvantages of conventional systemic therapies
- Expert insight: conventional systemic therapies
- Advantages and disadvantages of topical therapies
- Expert insight: topical therapies
- Medical practice
- Overview
- Drug selection
- Factors influencing drug selection in moderate to severe psoriasis
- Preferred treatment of psoriasis by disease location and comorbidities
- Region-specific treatment practices
- Treatment Decision Tree for Psoriasis: United States
- Treatment Decision Tree for Psoriasis: France
- Treatment Decision Tree for Psoriasis: Germany
- Treatment Decision Tree for Psoriasis: Italy
- Treatment Decision Tree for Psoriasis: Spain
- Treatment Decision Tree for Psoriasis: United Kingdom
- Treatment Decision Tree for Psoriasis: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in psoriasis
- Top unmet needs in psoriasis: current and future attainment
- Expert insight: unmet needs in moderate to severe psoriasis
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Therapies in late-phase development for psoriasis
- Estimated launch dates of key emerging therapies for the treatment of psoriasis
- Piclidenoson profile
- Analysis of the clinical development program for piclidenoson
- Expert insight: piclidenoson
- Expectations for launch and sales opportunity of piclidenoson in psoriasis
- Likely uses of piclidenoson in the treatment of psoriasis
- Deucravacitinib profile
- Key ongoing clinical trials of deucravacitinib in the treatment of psoriasis
- Analysis of the clinical development program for deucravacitinib
- Expert insight: deucravacitinib
- Expectations for launch and sales opportunity of deucravacitinib in psoriasis
- Likely uses of deucravacitinib in the treatment of psoriasis
- Early-phase pipeline analysis
- Select compounds in early-phase development for psoriasis
- Key discontinuations and failures in psoriasis
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in psoriasis: United States
- General reimbursement environment: United States
- Key market access considerations in psoriasis: EU5
- General reimbursement environment: EU5
- Key market access considerations in psoriasis: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Psoriasis bibliography
- Key findings
Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Previously, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.
Navya Vardhan, M.Sc., is an associate epidemiologist at Clarivate. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.